Skip to Main Content

Author Details

Allison Steigler
University of Newcastle
1999
50
22
PMIDPaper TitleJournal TitlePublished Year
37802226Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR.Int J Radiat Oncol Biol Phys2024
34955242Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial.Pathology2022
35469702High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.Eur Urol2022
35934601Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).Eur Urol2022
35051385Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.Lancet Oncol2022
35050303Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.JAMA Oncol2022
32285460Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial.Histopathology2020
31937919Tumour innervation and neurosignalling in prostate cancer.Nat Rev Urol2020
32092343Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial.Int J Radiat Oncol Biol Phys2020
32745667Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials.Radiother Oncol2020
32596153External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost.Front Oncol2020
32793485Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials.Front Oncol2020
32673785Rectal and Urethro-Vesical Subregions for Toxicity Prediction After Prostate Cancer Radiation Therapy: Validation of Voxel-Based Models in an Independent Population.Int J Radiat Oncol Biol Phys2020
30579763Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.Lancet Oncol2019
29122360Association between treatment planning and delivery factors and disease progression in prostate cancer radiotherapy: Results from the TROG 03.04 RADAR trial.Radiother Oncol2018
29222833Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: An exploratory analysis from the TROG 03.04 RADAR trial.J Med Imaging Radiat Oncol2018
27240216Measuring personal and functional changes in prostate cancer survivors: development and validation of the FADE: data from the TROG 03.04 RADAR trial.Psychooncology2017
28318448Psychological resilience aspects that mediate the depressive effects of urinary incontinence in prostate cancer survivors 10 years after treatment with radiation and hormone ablation.J Psychosoc Oncol2017
28004451Total depression and subtypes in prostate cancer survivors 10 years after treatment.Eur J Cancer Care (Engl)2017
27528117Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.Radiother Oncol2016
26072289Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial.Radiother Oncol2015
26325671Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data.Pathology2015
24512527Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.BJU Int2014
25130995Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.Lancet Oncol2014
23763887Picking the optimal duration of hormonal therapy in men with high-risk and locally advanced prostate cancer treated with radiotherapy.Semin Radiat Oncol2013
23618502Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer.Radiother Oncol2013
22112793Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials.Lancet Oncol2012
23320177Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial.Prostate Cancer2012
22310055Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term.Oncology2012
20350786A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial.Int J Radiat Oncol Biol Phys2011
22042952Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer.J Clin Oncol2011
21962824Another form of subgroup to beware.Radiother Oncol2011
21440505Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.Lancet Oncol2011
21257216A methodology for the analysis of PSA response signatures.Radiother Oncol2011
20606099Value of combined androgen blockade in the neoadjuvant treatment of localized prostate cancer: the jury must remain out.J Clin Oncol2010
18952309Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial.Radiother Oncol2009
19691097Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?Cancer2009
19577859Measuring time to biochemical failure in the TROG 96.01 trial: when should the clock start ticking?Int J Radiat Oncol Biol Phys2009
19176272Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer.Int J Radiat Oncol Biol Phys2009
18992951PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer?Radiother Oncol2009
18929505Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial.Lancet Oncol2008
17397033Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate.Cancer2007
17557956Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.J Clin Oncol2007
15727608Absence of adverse early quality of life outcomes of radiation therapy in breast conservation therapy for early breast cancer.Australas Radiol2005
16271786Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation.Radiother Oncol2005
16257791Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.Lancet Oncol2005
14768750Impact of radiation therapy on acute toxicity in breast conservation therapy for early breast cancer.Clin Oncol (R Coll Radiol)2004
12801045Relapse patterns after chemo-radiation for carcinoma of the oesophagus.Clin Oncol (R Coll Radiol)2003
10761262A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01).Australas Radiol2000
10901907Quality assurance audit in an Australasian phase III trial of accelerated radiotherapy for head and neck cancer (TROG 91.01). Trans-Tasman Radiation Oncology Group.Australas Radiol1999
  • 1 - 50 of 50

Recommended Authors

Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 14
William C Jackson
University of Michigan ann arbor
Career Start Year 2013
Number of shared co-authors 40
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 12
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 4
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Career Start Year 2008
Number of shared co-authors 4
John Thoms
Memorial University
Career Start Year 2008
Number of shared co-authors 4
Bridget F Koontz
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 20
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 1
Piet Ost
Ghent University, GZA Ziekenhuizen
Career Start Year 2002
Number of shared co-authors 27
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 9
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2000
Number of shared co-authors 17
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 27
Mark K Buyyounouski
Stanford University
Career Start Year 1999
Number of shared co-authors 28
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 4
Gert De Meerleer
University Hospitals Leuven
Career Start Year 1997
Number of shared co-authors 14
Andrew Loblaw
Princess Margaret Hospital, University of Toronto
Career Start Year 1995
Number of shared co-authors 19
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 9
William Robert Lee
Duke University School of Medicine
Career Start Year 1993
Number of shared co-authors 34
Richard Choo
Mayo Clinic
Career Start Year 1991
Number of shared co-authors 48
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Career Start Year 1990
Number of shared co-authors 59
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 15
Christopher R King
University of California los angeles
Career Start Year 1988
Number of shared co-authors 43
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year 1987
Number of shared co-authors 12
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 12
Eric J Small
University of California san francisco
Career Start Year 1985
Number of shared co-authors 21
Eric A Klein
Cleveland Clinic
Career Start Year 1984
Number of shared co-authors 57
Maha Hussain
Northwestern University
Career Start Year 1984
Number of shared co-authors 12
Oliver Sartor
Tulane University School of Medicine
Career Start Year 1983
Number of shared co-authors 26
Mario A Eisenberger
Johns Hopkins University
Career Start Year 1977
Number of shared co-authors 19
Alan Pollack
University of Miami Miller School of Medicine
Career Start Year 1963
Number of shared co-authors 28

Collaborators

James W Denham
University of Newcastle
Co-authored papers 47
David Joseph
Sir Charles Gairdner Hospital
Co-authored papers 36
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 5
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers 5
Michael L Steinberg
University of California los angeles
Co-authored papers 5
Amar U Kishan
University of California los angeles
Co-authored papers 5
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 4
Ming-Hui Chen
Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School
Co-authored papers 4
Anthony V D'Amico
Duke University Medical Center
Co-authored papers 4
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 4
Michel Bolla
universite Grenoble-Alpes (UGA)
Co-authored papers 4
Nicholas G Zaorsky
University Hospitals Seidman Cancer Centre, Cleveland Medical Centre
Co-authored papers 4
Ting Martin Ma
University of Washington
Co-authored papers 4
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 4
Tahmineh Romero
David Geffen School of Medicine at university of california los angeles
Co-authored papers 4
Michael Xiang
University of California los angeles
Co-authored papers 3
Philippe Maingon
Pitie-Salpetriere Hospital, AP-HP.Sorbonne Universite
Co-authored papers 3
Theo M de Reijke
Amsterdam University Medical Centers, University of Amsterdam
Co-authored papers 3
Araceli Guerrero
Hospital Son Espases
Co-authored papers 3
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 3
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Almudena Zapatero
University Hospital La Princesa
Co-authored papers 3
Lars Egevad
Karolinska Institute
Co-authored papers 3
Thomas M Pisansky
Mayo Clinic
Co-authored papers 3
Xavier Maldonado
Hospital Universitari Vall d'Hebron
Co-authored papers 3
Jeff M Michalski
Washington University School of Medicine
Co-authored papers 2
John R Srigley
University of Toronto
Co-authored papers 2
Robert T Dess
University of Michigan ann arbor
Co-authored papers 2
Jay P Ciezki
Cleveland Clinic
Co-authored papers 1
Jeffrey J Tosoian
Vanderbilt University Medical Center
Co-authored papers 1
Release 1.2